GLP-1 Packaging: Secondary Packaging, Kitting and Cold Chain Solutions

From blockbuster obesity treatments to expanding diabetes indications, GLP-1 therapies are driving new demands for pharmaceutical packaging and commercialization. As demand accelerates and new market entrants emerge, the focus is shifting beyond drug development to the packaging infrastructure needed to efficiently bring these therapies to market.

While many GLP-1 therapies are manufactured and supplied in primary formats such as pre-filled syringes or injector pens, pharmaceutical companies increasingly rely on specialized contract packaging partners to transform these products into compliant, market-ready configurations through secondary packaging, kitting and labelling services.

The packaging challenges emerging in the GLP-1 market also reflect broader trends across biologics, specialty pharmaceuticals and combination drug products.

Why GLP-1 Packaging Matters

As demand for injectable therapies grows, pharmaceutical companies need packaging partners that can deliver compliant secondary packaging, patient-ready kitting, serialization and market-specific configurations without delaying commercialization.

The Packaging Challenges Facing GLP-1 Therapies

In many cases, manufacturers supply GLP‑1 products as primary packaged units without:

• final labelling and serialization
• retail-ready secondary packaging
• integrated accessories or patient-use components
• region-specific configurations

This creates a critical gap between manufacturing and commercialization. While innovators focus on drug development and fill-finish operations, downstream packaging, labelling and market-specific configuration are often outsourced to specialized contract packaging providers that transform primary packaged products into compliant, market-ready formats.

Secondary Packaging for GLP-1 Injectable Therapies

GLP‑1 therapies highlight the importance of flexible, compliant secondary packaging systems, including cartoning, labelling, serialization, tamper-evident solutions, regulatory documentation and leaflet or IFU insertion.

Secondary packaging also enables adaptation across different geographies, retail channels and regulatory environments, allowing pharmaceutical companies to commercialize efficiently without reconfiguring upstream manufacturing.

Kitting and Combination Packaging for Injectable Therapies

A key trend emerging in GLP-1 and similar injectable therapies is the move toward combination packaging, where multiple components are packaged into a single patient-ready system. Kitting helps manufacturers reduce supply chain complexity, simplify fulfillment and improve the patient experience by delivering all required components in one package, such as:

• Injector or syringe
• Needles or accessories
• Instructions for use
• Supporting materials or packaging inserts

Beyond traditional pharmacy formats, kitting is also being used to support:

• Export markets
• Direct-to-patient models
• Retail-ready bundled configurations

This shift toward multi-component packaging increases complexity and reinforces the need for specialized contract packaging capabilities.

Cold Chain Considerations and Packaging Coordination

GLP‑1 therapies are temperature-sensitive injectable medications, requiring controlled handling throughout storage and distribution. While packaging itself is only one part of the system, it plays an essential role in enabling cold chain execution.

Packaging programs must be carefully aligned with cold chain strategies to support temperature-sensitive products during handling, conversion and distribution. Although secondary packaging is only one component of the cold chain, packaging providers must coordinate closely with qualified logistics partners to protect product integrity while maintaining commercialization timelines.

Scaling Packaging for Emerging Injectable Therapies

As competition within the GLP‑1 category increases, packaging requirements will continue to evolve. Pharmaceutical companies will need partners capable of supporting lower-volume, higher-mix production environments, managing packaging transfers and enabling rapid market entry in tightly regulated conditions.

These challenges extend well beyond GLP-1 therapies and reflect a broader industry shift toward increasingly complex injectable, specialty and combination drug products.

A Flexible Approach to Complex Pharmaceutical Packaging

The growth of GLP-1 therapies reinforces a broader industry trend: packaging is no longer simply a downstream operation—it is a critical component of commercialization strategy.

Jones Healthcare Group brings together secondary packaging, kitting, serialization, labelling, specialized packaging services and a cold chain-enabled partner network within an integrated platform, helping pharmaceutical companies simplify supply chains, adapt to evolving regulatory requirements and accelerate time to market. As injectable therapies continue to evolve, packaging partners that can bridge the gap between manufacturing and commercialization will play an increasingly strategic role.

Learn how Jones Healthcare Group supports pharmaceutical commercialization through integrated secondary packaging, kitting and specialized packaging services on the company’s website.